Seed · Medtech & Devices · Geneva, Switzerland · Founded 2019 · 11–25 employees
Terapet is a CERN spin-off developing breakthrough gamma-ray detection systems for proton therapy and nuclear medicine. Their flagship product Qualγscan enables real-time, 3D dose monitoring during proton therapy treatments, addressing a critical safety gap in cancer care. The company has commercialized their first product and secured CHF 2.3 million in seed funding from EFI Lake Geneva Ventures and Nina Capital in 2023. They're developing a second product, Nuclyscan, a total-body PET scanner for precision medicine deployment in 2026.
No open roles listed right now.